Use of K-plus channel activators - for prophylaxis of asthma and for treating other obstructive or inflammatory airway disorders

摘要

The use of four cpds. of formulae (I)-(II) is claimed. (I) and its derivs. are described in GB1489879, EP-314446, EP-273262, EP-298452, EP-339562, EP-344747, EP-296975, EP-312432, EP-327127 and EP-277612. The use of 10 cpds. is specifically claimed, including (-)-(3S,4R)-3,4-dihydro-3 -hydroxy-2,2-dimethyl-4-(2-oxo -1-cyclopent-1-enyloxy)-2H-1 -benzopyran-6-carbonitrile (PCO400). USE/ADVANTAGE - For the prophylaxis of obstructive or inflammatory respiratory disturbances (claimed), e.g., pneumoconiosis and asthma. The cpds. may also be used to treat acute hypersensitive reactions caused by allergic reaction or other irritations of the immune system. A method for treating ''morning dipping'' is also claimed. The cpds. are known K(+) channel activators. For prophylaxis of asthma, the oral dose of (I) (esp. PCO400) is 0.5-1.0mg, administered 1-3 times daily for up to 6 months. The dose may subsequently be reduced to 0.25-0.5 mg/day. For treatment of morning dipping, oral dose of PCO400 is 0.1-2(0.2-1) mg/day.